Volume 11, Number 16 of @Oncotarget reported that the prevalence of ipilimumab-related toxicity was associated with the patient to the duration of ipilimumab exposure, radiographic responses, progression-free survival, and overall survival.
The number of agents combined with ipilimumab on trial was associated with the average number of grade 3/4 toxicities ipilimumab monotherapy versus ipilimumab + 1 agent versus ipilimumab + 2 agents.
A number of low-grade toxicities were associated with duration of treatment, Pearson correlation coefficient r = 0.456; whereas the number of high-grade toxicities was not, r = 0.032.
Dr. Aman Chauhan from the Division of Medical Oncology, University of Kentucky said, "Cancer clinical trials offer the best data to study, treat, and cure cancer."
"Cancer clinical trials offer the best data to study, treat, and cure cancer."
- Dr. Aman Chauhan, The Division of Medical Oncology, University of Kentucky
The number of ipilimumab users in cancer clinics has expanded substantially and ipilimumab currently serves as one of the most often combined cancer immunotherapy agents against cancer.
In this retrospective article, the authors collect and analyze ipilimumab-attributed toxicity from 11 National Cancer Institute-sponsored phase 1 trials evaluating the agent in a variety of adult solid and hematological cancers with the aims of associating patient and clinical factors with engendered ipilimumab-attributed toxicity and treatment outcomes.
The Chauhan Research Team concluded in their Oncotarget Research Article that unlike chemotherapy, where tolerability depends on the baseline performance status of the patient as therapy is taxing on healthy tissue, immunotherapy side effects are often auto-immune driven which are unpredictable and theoretically unrelated to baseline performance status.
Although minimal prospective data exist on the effect of ECOG performance status in response to ipilimumab, retrospective analyses have suggested associations between ECOG performance status and survival but not with toxicity.
Sign up for free Altmetric alerts about this article
DOI - https://doi.org/10.18632/oncotarget.27537
Full text - https://www.oncotarget.com/article/27537/text/
Correspondence to - Aman Chauhan - [email protected]
Keywords -
immunotherapy,
toxicity,
co-administered agents,
metastatic melanoma,
immune checkpoint inhibitors
About Oncotarget
Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
[email protected]
18009220957x105
